Bristol-Myers Squibb succession
Confirmation of Wayne Davidson as the top pharmaceutical officer in the combined businesses has rekindled interest in the post-Gelb management. Chairman Richard Gelb has set June 1993 as the target for his retirement. At that date, current Vice Chairman William Miller will be 64. Likely replacement will come from current triumverate of exec VPs: Davidson, Charles Heimbold and Michael Autera. Heimbold, 56, has responsibility for consumer products, the health care group (medical devices) and planning and development. Autera is chief financial officer and head of administration, a key post in a major merger period.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.